I-BASE HIV TREATMENT BULLETINImportant note: Information in this article was accurate in August 2003. The state of the art may have changed since the publication date.
Click here to return to I-BASE main menu
DonateNow
Print this Article

Reduced bone mineral density in HIV-positive women

HIV Treatment Bulletin - August / September 2003


In the last oral presentation at the workshop, Steven Grinspoon presented results from an observational study showing significantly reduced bone mineral density in HIV-positive women compared to BMI and age-matched HIV-negative women. [1]

The study from Massachusetts General Hospital compared results from DEXA and hormonal indices of 84 HIV-positive women to 63 HIV-negative controls (mean age 41, BMI 26-27, 50-60% Caucasian). Bone density and T score were significantly reduced in the HIV-positive women at lumbar spine and hip (p=0.03 and p=0.04 respectively) compared to controls.

Osteopenia was demonstrated in 54% versus 30% (p=0.004) and osteoporosis in 10% versus 5% (p=0.27). 1,25-dihydroxyvitamin D was reduced and urinary NTx and osteoprotegrin both increased in the HIV-positive group but serum calcium, phosphorus, estradiol, FSH, PTH, osteocalcin and 25-hydroxyvitamin D levels were similar in both groups.

Among the HIV-positive women, bone density correlated with body mass and total body fat (both p<0.001) and negatively with urinary NTx.

Increased bone resorption, together with altered nutritional status, hormonal function and body composition may be responsible for these changes and, given that women are at increased risk for osteopenia, suggests that integrating bone density monitoring should be an important part of care for HIV-positive women.

Ref: Grinspoon S, Dolan SE, Huang JS et al – Reduced bone mineral density in HIV-infected women. Antiviral Therapy 2003; 8:L20:(Abstract 24.

030810
IB30407-16


©2003. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.